JCR Pharmaceuticals Co., Ltd.
Research JCR Pharmaceuticals Co., Ltd. (JCR) on Bullrun: market cap EUR 341.65M, P/E 28.0, dividend yield 3.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJCR
- ExchangeF
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Market capEUR 341.65M
- P/E28.0
- Dividend yield3.8%
- Financial periodFY2026
- RevenueJPY 40.32B
- Revenue growth21.9%
- Net incomeJPY 2.18B
- Free cash flow-JPY 11.72B
- Gross margin74.9%
Valuation Snapshot
latest market cap is EUR 341.65M; P/E is 28.0; dividend yield is 3.8%.
Peer valuation comparison
Latest P/E is 28x versus a Healthcare sector median of 24.46x (14.5% above).
Latest dividend yield is 3.83% versus a Healthcare sector median of 2.11% (81.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 40.32B | JPY 2.18B | -JPY 11.72B | 74.9% | 17.87 | JPY 14.01B | JPY 53.89B | JPY 46.94B |
| FY2025 | JPY 33.07B | -JPY 4.76B | -JPY 15.37B | 65.7% | -38.43 | JPY 13.20B | JPY 38.11B | JPY 47.04B |
| FY2024 | JPY 42.87B | JPY 5.51B | JPY 7.79B | 72.9% | 43.92 | JPY 18.76B | JPY 23.30B | JPY 56.18B |
| FY2023 | JPY 34.34B | JPY 3.77B | -JPY 14.06B | 74.1% | 30.22 | JPY 13.28B | JPY 22.80B | JPY 52.16B |
| FY2022 | JPY 51.08B | JPY 14.51B | -JPY 2.12B | 79.5% | 116.8 | JPY 30.73B | JPY 18.10B | JPY 50.88B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 341.65M | 28.0 | 3.9% | 0.11 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.11 EUR, yield 3.8%.
| Year | Dividends/share |
|---|---|
| FY2026 | 0.05 JPY |
| FY2025 | 0.11 JPY |
| FY2024 | 0.05 JPY |
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is JCR Pharmaceuticals Co., Ltd.'s market cap?
JCR Pharmaceuticals Co., Ltd.'s market capitalization is EUR 341.65M.
What is JCR Pharmaceuticals Co., Ltd.'s P/E ratio?
JCR Pharmaceuticals Co., Ltd.'s price-to-earnings (P/E) ratio is 28.0.
Does JCR Pharmaceuticals Co., Ltd. pay a dividend?
JCR Pharmaceuticals Co., Ltd. has a dividend yield of 3.8%.
What does JCR Pharmaceuticals Co., Ltd. do?
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.